Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells

Blood

Volumn 119, Issue 20, 2012, Pages 4636-4644

  Shao, Qianqian ^a   Ning, Hao ^b   Lv, Jiaju ^b   Liu, Yanguo ^a   Zhao, Xin ^c   Ren, Guangwen ^c   Feng, Alei ^a   Xie, Qi ^a   Sun, Jintang ^a   Song, Bingfeng ^a   Yang, Yongmei ^a   Gao, Wenjuan ^a   Ding, Kejia ^b   Yang, Meixiang ^a   Hou, Ming ^a   Peng, Jun ^a   Qu, Xun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD SAMPLING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; MALE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT; UPREGULATION;

EID: 84861204062     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-376418     Document Type: Article

References (50)

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767-811. (Pubitemid 30365397)
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673): 245-252. (Pubitemid 28155090)
3. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3(12):984-993. (Pubitemid 37521540)
4. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-1569.
5. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000;1(3): 199-205.
6. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6(6):476-483.
7. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-145. (Pubitemid 33741967)
8. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol. 2010;11(8):647-655.
9. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133-146. (Pubitemid 37328691)
10. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1):267-283. (Pubitemid 30119906)
11. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55-71.
12. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem. 1992;267(24):17321-17326.
13. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(19):3719-3727. (Pubitemid 35203598)
14. Lui EL, Loo WT, Zhu L, Cheung MN, Chow LW. DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. Biomed Pharmacother. 2005;59(suppl 2):S363-S365.
15. Fendrich V, Slater EP, Heinmoller E, et al. Alterations of the tissue inhibitor of metalloproteinase-3 (TIMP3) gene in pancreatic adenocarcinomas. Pancreas. 2005;30(2):e40-e45.
16. Liu MC, Choong DY, Hooi CS, Williams LH, Campbell IG. Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer. Cancer Lett. 2007;247(1):91-97. (Pubitemid 44959410)
17. Masson D, Rioux-Leclercq N, Fergelot P, et al. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer. 2010;46(8):1430-1437.
18. Ahonen M, Poukkula M, Baker AH, et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene. 2003;22(14):2121-2134. (Pubitemid 36539562)
19. Tran PL, Vigneron JP, Pericat D, et al. Gene therapy for hepatocellular carcinoma using nonviral vectors composed of bis guanidinium-trencholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther. 2003;10(6):435-444. (Pubitemid 36667129)
20. Edwards DR. TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges. J Pathol. 2004;202(4):391-394. (Pubitemid 38456156)
21. Finan KM, Hodge G, Reynolds AM, et al. In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer. 2006;53(3):273-284. (Pubitemid 44189570)
22. Zhang L, Zhao L, Zhao D, et al. Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3. Cancer Gene Ther. 2010;17(3):171-179.
23. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008;99(8): 1501-1506.
24. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24-37. (Pubitemid 43053650)
25. Black RA. TIMP3 checks inflammation. Nat Genet. 2004;36(9):934-935. (Pubitemid 39167484)
26. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type 1 polarized immune response. Blood. 2004;103(7): 2645-2647. (Pubitemid 38393019)
27. Yang M, Ma C, Liu S, et al. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology. 2009; 128(1 suppl):e237-e249.
28. Osman M, Tortorella M, Londei M, Quaratino S. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology. 2002;105(1): 73-82. (Pubitemid 34128042)
29. Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol. 2003;24(6):314-319.
30. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-2147. (Pubitemid 26086851)
31. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-1254.
32. Fukao T, Tanabe M, Terauchi Y, et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol. 2002;3(9):875-881.
33. Utsugi M, Dobashi K, Ono A, et al. PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role. J Immunol. 2009;182(9):5225-5231.
34. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1(4):311-316.
35. Philpott NJ, Nociari M, Elkon KB, Falck-Pedersen E. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci U S A. 2004; 101(16):6200-6205. (Pubitemid 38520551)
36. Baravalle G, Park H, McSweeney M, et al. Ubiquitination of CD86 is a key mechanism in regulating antigen presentation by dendritic cells. J Immunol. 2011;187(6):2966-2973.
37. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996; 383(6603):787-793. (Pubitemid 26372655)
38. Liu XG, Ma SH, Sun JZ, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117(6):2061-2069.
39. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225-3229. (Pubitemid 32695003)
40. Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K. IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway. J Immunol. 2002;168(4):1895-1902. (Pubitemid 34135791)
41. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000; 275(40):31226-31232.
42. Troeberg L, Fushimi K, Khokha R, Emonard H, Ghosh P, Nagase H. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J. 2008;22(10):3515-3524.
43. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987-995. (Pubitemid 41057715)
44. Demangel C, Bertolino P, Britton WJ. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol. 2002; 32(4):994-1002. (Pubitemid 34428814)
45. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex transfer from CD14 to TLR4 and MD-2. J Biol Chem. 2001;276(24):21129-21135.
46. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191-1195.
47. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79(4):310-316. (Pubitemid 47390130)
48. Catani L, Fagioli ME, Tazzari PL, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol. 2006; 34(7):879-887.
49. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol. 2001;79:55-92. (Pubitemid 32977574)
50. Wang T, Zhao H, Ren H, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 2005;90(7):914-923. (Pubitemid 41020294)